- Home
- CRIS vs LRE Comparison
CRIS vs LRE Comparison
Compare CRIS & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- LRE
- Stock Information
- Founded
- CRIS 2000
- LRE 2001
- Country
- CRIS United States
- LRE Japan
- Employees
- CRIS N/A
- LRE N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- LRE
- Sector
- CRIS Health Care
- LRE
- Exchange
- CRIS Nasdaq
- LRE Nasdaq
- Market Cap
- CRIS 21.3M
- LRE 17.6M
- IPO Year
- CRIS 2000
- LRE 2023
- Fundamental
- Price
- CRIS $2.27
- LRE $1.86
- Analyst Decision
- CRIS Strong Buy
- LRE
- Analyst Count
- CRIS 2
- LRE 0
- Target Price
- CRIS $16.50
- LRE N/A
- AVG Volume (30 Days)
- CRIS 75.5K
- LRE 21.0K
- Earning Date
- CRIS 07-31-2025
- LRE 01-01-0001
- Dividend Yield
- CRIS N/A
- LRE N/A
- EPS Growth
- CRIS N/A
- LRE N/A
- EPS
- CRIS N/A
- LRE 0.29
- Revenue
- CRIS $11,202,000.00
- LRE $117,804,154.00
- Revenue This Year
- CRIS N/A
- LRE N/A
- Revenue Next Year
- CRIS $10.67
- LRE N/A
- P/E Ratio
- CRIS N/A
- LRE $5.55
- Revenue Growth
- CRIS 14.17
- LRE 8.82
- 52 Week Low
- CRIS $1.02
- LRE $1.10
- 52 Week High
- CRIS $8.29
- LRE $2.92
- Technical
- Relative Strength Index (RSI)
- CRIS 50.37
- LRE 63.60
- Support Level
- CRIS $2.11
- LRE $1.64
- Resistance Level
- CRIS $2.26
- LRE $1.83
- Average True Range (ATR)
- CRIS 0.20
- LRE 0.16
- MACD
- CRIS -0.04
- LRE -0.02
- Stochastic Oscillator
- CRIS 16.85
- LRE 40.86
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.